[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[S. 1069 Introduced in Senate (IS)]
<DOC>
115th CONGRESS
1st Session
S. 1069
To establish pilot projects in order to provide timely and reliable
information on the safety and effectiveness of cleared or approved
devices.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
May 8, 2017
Mr. Casey (for himself, Ms. Warren, and Mr. Franken) introduced the
following bill; which was read twice and referred to the Committee on
Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To establish pilot projects in order to provide timely and reliable
information on the safety and effectiveness of cleared or approved
devices.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Medical Device Safety Monitoring
Act''.
SEC. 2. DEVICE PILOT PROJECTS.
(a) Postmarket Pilot.--Section 519 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 360i) is amended by adding at the end the
following:
``(i) Pilot Projects.--
``(1) In general.--In order to provide timely and reliable
information on the safety and effectiveness of cleared or
approved devices, including responses to adverse events and
malfunctions, and to advance the objectives of part 803 of
title 21, Code of Federal Regulations (or successor
regulations), and advance the objectives of, and evaluate
innovative new methods of compliance with, this section and
section 522, the Secretary shall, within one year of the date
of enactment of this subsection, initiate one or more pilot
projects for voluntary participation by a manufacturer or
manufacturers of device or device type, or continue existing
projects in accordance with paragraph (3), that meet all of the
following requirements:
``(A) Are designed to efficiently generate reliable
and timely safety and active surveillance data for use
by the Secretary or manufacturers of the devices that
are involved in the pilot project.
``(B) Inform the development of methods, systems,
data criteria, and programs that could be used to
support safety and active surveillance activities for
devices not included in such project.
``(C) Are designed and conducted in coordination
with a comprehensive system for evaluating medical
device technology that operates under a governing board
with appropriate representation of stakeholders,
including consumer groups and device manufacturers.
``(D) Use electronic health data including claims
data, patient survey data, and any other data, as the
Secretary determines appropriate.
``(E) Prioritize devices and device types that meet
one or more of the following criteria:
``(i) Devices and device types for which
the collection and analysis of real world
evidence regarding a device's safety and
effectiveness is likely to advance public
health.
``(ii) Devices and device types that are
widely used.
``(iii) Devices and device types, the
failure of which has significant health
consequences.
``(iv) Devices and device types for which
the Secretary has received public
recommendations in accordance with paragraph
(2)(B) and has determined to meet one of the
criteria under clauses (i) through (iii) and is
appropriate for a project under this
subsection.
``(2) Participation.--The Secretary shall establish the
conditions and processes for--
``(A) authorizing voluntary participation of a
manufacturer of a device in the pilot project described
in paragraph (1); and
``(B) facilitating public recommendations for
devices to be prioritized under the pilot project
described in paragraph (1), including requirements for
the data necessary to support such recommendation.
``(3) Implementation.--The Secretary may satisfy the
requirements of paragraphs (1) and (2) by continuing or
expanding existing projects, or by beginning new projects, that
meet the criteria of subparagraphs (A) through (E) of paragraph
(1) or by entering into contracts, cooperative agreements,
grants, or other appropriate agreements with public or private
entities that have a significant presence in the United States,
and meet the following additional conditions:
``(A) If such public or private entities are a
component of another organization, the entities have
established appropriate security measures to maintain
the confidentiality and privacy of the data described
in paragraph (1)(D) and the entity shall not make an
unauthorized disclosure of such data to the other
components of the organization in breach of such
confidentiality and privacy requirements.
``(B) In the case of the termination or nonrenewal
of such contracts, cooperative agreements, grants, or
other appropriate agreements, the entities shall comply
with each of the following:
``(i) Continue to comply with the
confidentiality and privacy requirements under
this subsection with respect to all data
disclosed to the entity.
``(ii) Return any data disclosed to such
entity under this subsection to which it would
not otherwise have access or, if returning the
data is not practicable, destroy the data.
``(C) Have at least one of the following
qualifications:
``(i) Research, statistical, epidemiologic,
or clinical capability and expertise to conduct
and complete the activities under this
subsection, including the capability and
expertise to provide the Secretary access to
de-identified data consistent with the
requirements of this subsection.
``(ii) An information technology
infrastructure in place to support electronic
data and operational standards to provide
security for such data, as appropriate.
``(iii) Experience with, and expertise on,
the development of device safety and
effectiveness research and surveillance using
electronic health data.
``(iv) Other expertise which the Secretary
determines necessary to fulfill the activities
under this subsection.
``(4) Review of contract in the event of a merger or
acquisition.--The Secretary shall review a contract with a
qualified entity under this subsection in the event of a merger
or acquisition of the entity in order to ensure that the
requirements under this subsection will continue to be met.
``(5) Report to congress.--Not later than 18 months after
the date of enactment of this subsection, and annually
thereafter, the Secretary shall submit to the Committee on
Health, Education, Labor, and Pensions of the Senate and the
Committee on Energy and Commerce of the House of
Representatives a report containing a description of the pilot
projects being conducted pursuant to this subsection, including
for each pilot project--
``(A) how the project is being implemented in
accordance with paragraph (3) and the contractor or
grantee as applicable;
``(B) the number of manufacturers that have agreed
to participate;
``(C) the data sources used;
``(D) the devices or device categories involved;
and
``(E) the number of patients involved.
``(6) Compliance with requirements for records or reports
on devices.--The participation of a manufacturer in a pilot
project under this subsection shall not affect the eligibility
of such manufacturer to participate in any quarterly reporting
program implemented under this Act. The Secretary may determine
that, for the specified time period to be determined by the
Secretary, a manufacturer's participation in a pilot project
under this subsection may meet certain other requirements of
this section or section 522 if--
``(A) the project has demonstrated success in
capturing relevant adverse event information; and
``(B) the Secretary has established procedures for
making adverse event and safety information collected
from the pilot public, to the extent possible, if
collected pursuant to this section or section 522.
``(7) Privacy requirements.--With respect to the pilot
projects conducted pursuant to this subsection--
``(A) individual identifiable health information
shall not be disclosed when presenting any information
from such project; and
``(B) such projects shall comply with section
264(c) of the Health Insurance Portability and
Accountability Act of 1996 (42 U.S.C. 1320d-2 note) and
sections 552 and 552a of title 5, United States Code.
``(8) Other compliance.--Any pilot program undertaken in
coordination with the comprehensive system described in
paragraph (1)(C), including pilot projects under this
subsection, that relates to the use of real world evidence for
devices shall comply with paragraph (1)(B), the conditions
listed in subparagraphs (A) and (B) of paragraph (3), and
paragraphs (4), (5), (6), and (7).
``(9) Sunset.--This subsection shall cease to have force or
effect on October 1, 2022.''.
(b) Report.--Not later than January 31, 2021, the Secretary of
Health and Human Services, acting through the Commissioner of Food and
Drugs, shall conduct a review through an independent third party to
evaluate the strengths, limitations, and appropriate use of evidence
collected pursuant to real world evidence pilot projects described in
the letters described in section 201(b) of the Medical Device User Fee
Amendments of 2017 and subsection (i) of section 519 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 360i), as amended by subsection
(a), for informing premarket and postmarket decisionmaking for multiple
device types, and to determine whether the methods, systems, and
programs in such pilot projects efficiently generate reliable and
timely evidence about the effectiveness or safety surveillance of
devices.
<all>